preclinical white papers and articles

  1. A CRO's Way Forward In The Midst Of A Pandemic: QPS Operations And COVID-19 6/18/2021

    In this Q&A, QPS Holdings LLC Chairman President, and CEO, Ben Chien, Ph.D., reflects on the progress of the company’s growth from a small, three-person start-up to a mid-sized CRO, the impact COVID-19 has had on drug development and clinical trials, and the way forward for CROs in the midst of a pandemic.

  2. The Most Effective COVID-19 Vaccine Could Be Intranasal 6/17/2021

    Vaccine developers are looking at preventing the coronavirus from being transmitted by focusing on the nose and respiratory tract. An intranasal vaccine would trigger immune responses in the nose, throat and lung mucosa by targeting immunoglobulin A (IgA), antibodies which exist solely in the mucosa. The mucosa acts as a physical barrier to potential pathogens, trapping them before they have a chance to enter the body. Given this, the intranasal vaccine would prevent transmission from exhaled droplets or aerosols, as there would not be virus in the body to exhale.

  3. Covid-19 And Brain Fog: How Some Infections Affect The Neurological System 6/17/2021

    Difficulty thinking, concentrating, and remembering are amongst the most debilitating long-haul symptoms of COVID-19. In some cases, this “brain fog” can linger for months. New research helps explain how SARS-CoV-2, the virus that causes COVID-19, spreads to the brain and why some patients experience severe neurological symptoms while others do not.

  4. New Insight Into RNA And DNA Relationship Could Lead To New Antivirals 6/13/2021

    RNA viruses are known to cause a large number of diseases in humans, including COVID-19. One potentially valuable drug development avenue is identifying a mechanism that could halt the function of viral RNA polymerase (RNAP) — the enzyme that initiates RNA replication and thus propagates RNA viruses. In this blog review how a team from the University of Turku, Finland, and Penn State University discovered not only how viral RNA polymerase is triggered, but also how it avoids using DNA nucleotide building blocks, which are chemically similar to RNA.

  5. Pathology's Best-Kept Secret 3/25/2021

    Chief Pathologist John Cochran discusses how clinical trials offer pathologists the opportunity to work at the forefront of diagnostic discovery.

  6. Elevating Effective Outcomes With Companion Diagnostics 3/22/2021

    Companion diagnostics (CDx) is a keystone for pharma to create more precise drug therapies as personalized medicine accelerates. Here’s why a CDxcentral laboratory partner is necessary.

  7. 3 Ways To Survive The Shifts In Life Sciences 1/6/2021

    Over the past 20 years, the life sciences industry has undergone massive changes, and new software and partners have emerged. There are three key ways that business can serve the dynamic needs of modern drug development.

  8. 3 Ways To Mitigate Data Manipulation Risk In Drug Development 1/6/2021

    A critical output of the drug development process, besides the compound itself, is data. We highlight specific actions to mitigate your organization’s risk of data manipulation and three key steps in tackling this problem.

  9. Immunogenicity Assessment: As FDA Guidance Shifts, How Can You Reduce Clinical Hold Risks? 5/9/2020

    Biotechnology entrepreneurs face many challenges as they push to bring potential new drugs into the clinic, whether that means raising the necessary funds for a clinical trial or conducting adequate assessments that ensure drug safety and efficacy. One main concern is often challenging: keeping up with an ever-evolving regulatory guidance.

  10. Seven Essentials For Successful Drug Development 8/5/2019

    In reflecting on the differences between successful and unsuccessful clinical trials or programs, several factors consistently emerge as essential components of success and failure. This article reminds of the essentials so that effective therapies have a greater likelihood of reaching patients in need.